ACC: J&J, waiting for $1.5B FDA nod, touts more aspirin-topping Xarelto data in artery disease patients

Johnson & Johnson has bolstered its case for yet another Xarelto approval. Sunday at the American College of Cardiology meeting, new analyses showed that, compared with solo aspirin, the drug cut the incidence of major limb problems among peripheral artery disease (PAD) patients by 43%—and in turn cut down on amputations, death and hospitalizations.Original Article